Pink Sheet Podcast: Mid-Year Drug Approvals, Drug Pricing Hits And Misses, A Plea For More Naloxone, And Gottlieb Goes To Pfizer
Executive Summary
A look back at the implications of the mid-year approval total, developments in drug pricing efforts on and off Capitol Hill, the FDA's plea for generic naloxone, and former commissioner Scott Gottlieb heading to Pfizer's board of directors.
Senior writers Derrick Gingery and Michael Cipriano tackle the 2019 mid-year approval tally, which is not as fabulous as last year, and drug pricing developments in the House Energy and Commerce Committee, as well set-backs for regulations requiring direct-to-consumer TV ad price disclosure and the removing the safe harbor for drug rebates. The reporters also discuss another attempt by the US Food and Drug Administration to entice sponsors into markets lacking generic competition and former commissioner Scott Gottlieb's election to the Pfizer Inc. board of directors.
More On These Topics From The Pink Sheet
CDER Midyear Report: Sponsors Struggle With Drop In Novel Approval Rate
After The Peak Of 2018’s US FDA Approval Record, 2019 Looks Like A Valley
After DTC Rule Tossed Out In Court, Attention Turns (Again) To Congress
Pharma's Big Defeat: US Rebate Proposal Hits The End Of The Road
US FDA Asks Sponsors Of Discontinued Naloxones To Consider Return To Market
Gottlieb's Pfizer Board Seat: Quick, Bold, But Not Unusual For An Ex-Commish